# A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)

Source: https://onco.cc/trials/nct04471727/  
OnCo record `nct04471727` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Atezolizumab, Ifinatamab deruxtecan in small-cell lung cancer, run by Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), active and no longer recruiting.

## Summary

A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001) is a phase 1/2 interventional study registered as NCT04471727 by Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), with 232 participants planned, started 2020-12-14 and due to reach its primary completion in 2028-01-28. Interventions recorded: Gocatamig, Atezolizumab, Ifinatamab Deruxtecan (I-DXd). Conditions listed: Small-Cell Lung Cancer, Neuroendocrine Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04471727
- Phase: 1/2
- Setting: A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN328 Monotherapy and HPN328 With Atezolizumab or Ifinatamab Deruxtecan (I-DXd) in Patients With Advanced Cancers Associated With Expression of Delta-like Canonical Notch Ligand 3 (DLL3).
- Sponsor: Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Enrolled: 232

## Sources

- ClinicalTrials.gov NCT04471727: https://clinicaltrials.gov/study/NCT04471727

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Ifinatamab deruxtecan](https://onco.cc/drugs/ifinatamab-deruxtecan/)

---
JSON: https://onco.cc/api/v1/entities/nct04471727.json